{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:18:48Z","timestamp":1785903528358,"version":"3.56.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Given the rapid increase in novel treatments for patients with multiple myeloma (MM), this patient preference study aimed to establish which treatment attributes matter most to MM patients and evaluate discrete choice experiment (DCE) and swing weighting (SW) as two elicitation methods for quantifying patients\u2019 preferences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A survey incorporating DCE and SW was disseminated among European MM patients. The survey included attributes and levels informed by a previous qualitative study with 24 MM patients. Latent class and mixed logit models were used to estimate the DCE attribute weights and descriptive analyses were performed to derive SW weights. MM patients and patient organisations provided extensive feedback during survey development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>393 MM patients across 21 countries completed the survey (<jats:italic>M<\/jats:italic><jats:sub>years since diagnosis<\/jats:sub>=6; <jats:italic>M<\/jats:italic><jats:sub>previous therapies<\/jats:sub>=3). Significant differences (p&amp;lt;.01) between participants\u2019 attribute weights were revealed depending on participants\u2019 prior therapy experience, and their experience with side-effects and symptoms. Multivariate analyses showed that participants across the three MM patient classes identified <jats:italic>via<\/jats:italic> the latent class model differed regarding their past number of therapies (<jats:italic>F<\/jats:italic>=4.772, <jats:italic>p<\/jats:italic>=.009). Patients with the most treatments (class 1) and those with the least treatments (class 3) attached more value to life expectancy versus quality of life-related attributes such as pain, mobility and thinking problems. Conversely, patients with intermediary treatment experience (class 2) attached more value to quality of life-related attributes versus life expectancy. Participants highlighted the difficulty of trading-off between life expectancy and quality of life and between physical and mental health. Participants expressed a need for greater psychological support to cope with their symptoms, treatment side-effects, and uncertainties. With respect to patients\u2019 preferences for the DCE or SW questions, 42% had no preference, 32% preferred DCE, and 25% preferred SW.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Quality of life-related attributes affecting MM patients\u2019 physical, mental and psychological health such as pain, mobility and thinking problems were considered very important to MM patients, next to life expectancy. This underscores a need to include such attributes in decision-making by healthcare stakeholders involved in MM drug development, evidence generation, evaluation, and clinical practice. This study highlights DCE as the preferred methodology for understanding relative attribute weights from a patient\u2019s perspective. <\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.1027353","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T12:07:41Z","timestamp":1669723661000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["What matters most to patients with multiple myeloma? A Pan-European patient preference study"],"prefix":"10.3389","volume":"12","author":[{"given":"Rosanne","family":"Janssens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamika","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Vallejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Galinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananda","family":"Plate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"De Ronne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Verschueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Schoefs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneleen","family":"Vanhellemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Schjesvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cabezudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Vandebroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Huys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"B1","article-title":"Global approaches in myeloma: Critical trials that may change practice. American society of clinical oncology educational book","volume-title":"American Society of clinical oncology annual meeting","author":"Moreau","year":"2018"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-725705","article-title":"How I manage the toxicities of myeloma drugs","volume":"129","author":"Delforge","year":"2017","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.08.019","article-title":"Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France","volume":"19","author":"Despi\u00e9gel","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: Translating findings to the real-world setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01395","article-title":"Design, conduct, and use of patient preference studies in the medical product life cycle: A multi-method study","volume":"10","author":"van Overbeeke","year":"2019","journal-title":"Front Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-017-0253-9","article-title":"Health preference research: An overview","volume":"10","author":"Craig","year":"2017","journal-title":"Patient"},{"key":"B7","unstructured":"Patient preference information (PPI) in medical device decision-making 2020"},{"key":"B8","first-page":"189","article-title":"Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: A systematic review","volume-title":"BMC Med Inform Decis Mak.","author":"Janssens","year":"2019"},{"key":"B9","unstructured":"51326EMA regulatory science to 2025 - strategic reflection 202012"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-019-00367-w","article-title":"Patient preferences in the medical product life cycle: What do stakeholders think? semi-structured qualitative interviews in Europe and the USA","author":"Janssens","year":"2019","journal-title":"Patient"},{"key":"B11","unstructured":"Patient preferences in benefit risk assessments during the drug life cycle"},{"key":"B12","unstructured":""},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.686165","article-title":"Patient preferences for multiple myeloma treatments: A multinational qualitative study","volume":"8","author":"Janssens","year":"2021","journal-title":"Front Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12911-020-01142-w","article-title":"Appraising patient preference methods for decision-making in the medical product lifecycle: An empirical comparison","volume":"20","author":"Whichello","year":"2020","journal-title":"BMC Med Inform Decis Mak"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.595797","article-title":"Patient preferences to assess value IN gene therapies: Protocol development for the PAVING study in hemophilia","volume":"8","author":"van Overbeeke","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-015-0118-z","article-title":"Sample size requirements for discrete-choice experiments in healthcare: a practical guide","volume":"8","author":"de Bekker-Grob","year":"2015","journal-title":"Patient"},{"key":"B17","unstructured":"Velcade (bortezomib) dosing, indications, interactions, adverse effects, and more2019"},{"key":"B18","unstructured":"Revlimid\u00ae treatment and multiple myeloma 2019"},{"key":"B19","unstructured":"Revlimid (lenalidomide) dosing, indications, interactions, adverse effects, and more2019"},{"key":"B20","unstructured":"Kyprolis (carfilzomib) dosing, indications, interactions, adverse effects, and more2019"},{"key":"B21","unstructured":"Darzalex (daratumumab) dosing, indications, interactions, adverse effects, and more2019"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087671","article-title":"Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2014","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.353","article-title":"Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European myeloma network","volume":"32","author":"Ludwig","year":"2018","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx018","article-title":"Subjective and objective taste and smell changes in cancer","volume":"28","author":"Spotten","year":"2019","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2410-2","article-title":"The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood marrow Transplant J Am Soc Blood Marrow Transplantation"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"New Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.686165","article-title":"Patient preferences for multiple myeloma treatments: A multinational qualitative study","volume":"8","author":"Janssens","year":"2021","journal-title":"Front In Med"},{"key":"B29","unstructured":""},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4255","article-title":"MCDA swing weighting and discrete choice experiments for elicitation of patient benefit-risk preferences: A critical assessment","volume":"26","author":"Tervonen","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B31","unstructured":"EQ-5D-5L user guide: Basic information on how to use the EQ-5D-5L instrument2019"},{"key":"B32","article-title":"Brief questions to identify patients with inadequate health literacy","volume":"36","author":"Chew","year":"2004","journal-title":"Fam Med"},{"key":"B33","volume-title":"Qualitative Research Analysis. The NIHR RDS for the East Midlands\/ Yorkshire","author":"Lacey","year":"2007"},{"key":"B34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1634\/theoncologist.2017-0257","article-title":"Individual trade-offs between possible benefits and risks of cancer treatments: Results from a stated preference study with patients with multiple myeloma","volume":"23","author":"Postmus","year":"2018","journal-title":"Oncologist"},{"key":"B35","unstructured":"Measuring patient preferences: An exploratory study to determine how patient preferences data could be used in health technology assessment (HTA) 2019\n            MyelomaUK"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S259612","article-title":"Myeloma patient value mapping: A discrete choice experiment on myeloma treatment preferences in the UK","volume":"14","author":"Fifer","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"B37","first-page":"Doc10","volume-title":"Evaluating patients' preferences for multiple myeloma therapy, a discrete-Choice-Experiment","author":"M\u00fchlbacher","year":"2008"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X19873630","article-title":"From individual to population preferences: Comparison of discrete choice and dirichlet models for treatment benefit-risk tradeoffs","volume":"39","author":"Tervonen","year":"2019","journal-title":"Med decision making an Int J Soc Med Decision Making"},{"key":"B39","unstructured":"PREFER - patient preferences. PREFER's patient input to decision making under evaluation by EMA and EUnetHTA"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1027353\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T12:07:49Z","timestamp":1669723669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1027353\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":39,"alternative-id":["10.3389\/fonc.2022.1027353"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1027353","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"article-number":"1027353"}}